Inotrem

Biotech · Private

Nangibotide, a TREM-1 receptor antagonist small molecule therapeutic for sepsis and inflammatory shock

inotrem.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
2 granted · 4 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3232ROSEBUD BIOSCIENCES INC.——
3233Therapeutic Vision, Inc.——
3234Florica Therapeutics, Inc.——
3235Inotrem——
3236EyeBio——
3237Expedition Therapeutics——
3238SIRGA ADVANCED BIOPHARMA, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 6

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.